South Korea Medical Device Procurement: NHIS Reimbursement, MFDS Market Access & HTA Process Guide (2026)

Why South Korea Matters for Medical Device Manufacturers

South Korea is the fourth-largest medical device market in Asia Pacific and one of the most technologically advanced healthcare systems in the world. With universal national health insurance covering 97.2% of the population through a single-payer system, virtually all medical device purchasing flows through or is influenced by government reimbursement decisions.

The Korean medical device market is valued at approximately $7.5 billion (2025 estimate) and is expected to return to moderate growth in 2026 following a period of disruption from the 2024–2025 junior doctors' strike. US suppliers are already the largest foreign source of advanced medical technologies in Korea, making it a high-value market for international manufacturers.

Yet Korea's procurement and reimbursement system is uniquely complex. Unlike many markets where regulatory approval is sufficient for commercialization, Korea requires most new medical devices to pass a Health Technology Assessment (HTA) before they can be reimbursed under the National Health Insurance (NHI) system. This creates a dual-barrier: manufacturers must first obtain MFDS approval, and then navigate HTA evaluation by the National Evidence-based Healthcare Collaborating Agency (NECA) and reimbursement listing by the Health Insurance Review and Assessment Service (HIRA).

This guide explains the complete pathway from MFDS approval to NHIS reimbursement, the new Immediate Market Entry pathway launched in January 2026, and practical strategies for foreign manufacturers.

South Korea's Healthcare System and Procurement Structure

The Single-Payer Model

South Korea operates a single-payer National Health Insurance (NHI) system administered by the National Health Insurance Service (NHIS). Key features:

Feature	Details
Population covered	~52 million (97.2% enrollment)
System type	Single-payer, fee-for-service (93% of payments)
Administering body	NHIS (insurance) and HIRA (claims review and assessment)
Co-payment rate	Generally 20–60% depending on facility type and item category
Annual health expenditure	KRW 110 trillion ($82 billion) in total medical costs (2023); NHI benefit expenditures exceeded KRW 100 trillion in 2025

Key Institutions in Medical Device Procurement

Institution	Role
MFDS (Ministry of Food and Drug Safety)	Regulatory approval of medical devices; market authorization
NIDS (National Institute of Medical Device Safety Information)	Listing of Class 1 devices; certification of Class 2 devices
HIRA (Health Insurance Review and Assessment Service)	Reimbursement eligibility determination; coverage decisions; coding
NECA (National Evidence-based Healthcare Collaborating Agency)	Health Technology Assessment (HTA) for new medical technologies
NHIS (National Health Insurance Service)	Maximum reimbursement price (MRP) negotiation; insurance fund management
MOHW (Ministry of Health and Welfare)	Policy oversight; final coverage/non-coverage determination

MFDS Approval: The Regulatory Gateway

Device Classification

Korea classifies medical devices into four classes, aligned with the Global Harmonization Task Force (GHTF) framework:

Class	Risk Level	Approval Pathway	Review Body
Class I	Very Low	Listing (abbreviated technical document)	NIDS
Class II	Low	Certification (technical document + evidence report)	NIDS
Class III	Moderate	Approval (technical document + evidence report)	MFDS
Class IV	High	Approval (technical document + evidence report)	MFDS

Korea License Holder (KLH) Requirement

Foreign manufacturers must appoint a Korea License Holder (KLH) — a local entity that holds the marketing authorization on behalf of the foreign manufacturer. The KLH is legally responsible for:

• Submitting and maintaining the MFDS application
• Post-market surveillance reporting
• Recalls and field safety corrective actions
• Communication with MFDS and other Korean authorities

Approval Timeline

Class	Typical Timeline
Class I (NIDS listing)	2–4 weeks
Class II (NIDS certification)	3–6 months
Class III (MFDS approval)	6–12 months
Class IV (MFDS approval)	8–15 months

From Approval to Reimbursement: The HTA and Listing Process

This is where Korea's system diverges most significantly from other markets. MFDS approval alone does not guarantee that a device will be used in clinical practice or reimbursed. Most new medical devices — particularly those involving new medical procedures — must undergo Health Technology Assessment before they can be listed for reimbursement.

The Three Stages

Stage 1: Coverage Determination (HIRA)

When it is unclear whether a medical device is a covered or non-covered item under NHI, an application must be made to HIRA for an official determination. Eligible applicants include:

• Healthcare providers
• Medical professional associations
• Manufacturers or importers

Required documents include:

• MFDS marketing authorization (or application receipt)
• Written opinion on covered vs. non-covered classification
• Supporting scientific literature

Timeline: HIRA reports its assessment to MOHW within 70 days.

Stage 2: Health Technology Assessment (NECA)

For devices involving new medical technology (new procedures or techniques), a separate HTA must be completed by NECA before reimbursement listing can proceed. The HTA evaluates:

• Clinical safety
• Clinical effectiveness
• Cost-effectiveness

This is a strict gatekeeper — if a technology fails to demonstrate clinical safety or effectiveness, its entry into either covered or non-covered categories is fundamentally blocked.

Timeline: The time from MFDS approval to reimbursement listing for devices that pass HTA has historically ranged from 200 to 490 days.

Stage 3: Reimbursement Listing and Pricing (NHIS)

Once a device passes HTA (or is exempt), the manufacturer applies for reimbursement listing. The application includes:

• Copy of MFDS marketing authorization
• Proposed price and justification
• Cost-effectiveness evidence
• Domestic and international usage information
• Product composition and instructions for use
• Clinical literature and evidence of clinical usefulness

MOHW makes the final coverage/non-coverage determination within 30 days of receiving HIRA's report. If covered, a maximum reimbursement price (MRP) is established simultaneously.

The Integrated Decision

Korea's system integrates coding, payment, and coverage decisions into a single process. Once a new technology passes HTA and is approved for reimbursement:

• The procedure/device code is assigned
• The upper limit price is determined (if covered)
• The reimbursement ratio is set

All three elements are decided simultaneously, making the HTA outcome the critical decision point for market access.

Maximum Reimbursement Price (MRP) Methodology

Korea uses External Reference Pricing (ERP) as a key input for pricing decisions, referencing prices in the A8 countries: United States, Japan, United Kingdom, France, Germany, Italy, Switzerland, and Canada (added January 2023). A device's cost-effectiveness is recognized if its price is below the minimum price in these A8 countries. During NHIS negotiations, prices may be further adjusted referencing prices from other OECD countries.

Important Pricing Constraints for Foreign Manufacturers

Korea's reimbursement pricing defaults to the lowest price among existing predicate devices. A new device can only receive a higher price if HIRA determines it has significant clinical advantages — and even then, the price is typically set at the highest price among existing predicates, not based on the manufacturer's proposed price. For completely novel devices without predicates, a new price category may be established, but this price will almost always be lower than reimbursement prices in advanced Western countries. This has been a source of contention in US-Korea trade talks.

However, under the KORUS FTA (Korea-US Free Trade Agreement), US medical device companies can request an Independent Review Process of government pricing and maximum reimbursement determinations. This review is conducted by a body independent of MOHW, NHIS, and HIRA, providing a mechanism to challenge unfavorable pricing decisions.

The New Immediate Market Entry Pathway (2026)

Overview

On January 26, 2026, Korea launched a landmark reform: the "Market Immediate Entry Medical Technology" system. This pathway dramatically shortens the time for innovative medical devices to reach clinical use.

Key Features

Feature	Previous System	New Immediate Entry Pathway
Maximum time to clinical use	Up to 490 days	80–140 days
Separate HTA required	Yes	No (waived for qualifying devices)
Clinical evaluation during MFDS approval	Standard	Strengthened (international-level)
Eligible device categories	All	199 designated categories

Eligible Categories

The MFDS has designated 199 eligible device categories, including:

• 113 digital medical devices (including AI-enabled SaMD)
• 83 in vitro diagnostic reagents
• Other innovative devices including robotic surgical systems, robot-assisted orthopedic exercise devices, and powered exoskeletons

Target items include standalone software medical devices using AI, robotic surgical devices, IVD reagents, and powered exoskeletons.

How It Works

1. The device undergoes reinforced clinical evaluation during the MFDS authorization phase (complete data including institutional trials, scientific literature, and real-world data)
2. MFDS designates the device as an "immediate-entry medical technology" based on innovation criteria
3. The device can be used immediately in healthcare institutions after MFDS authorization — no separate HTA required
4. HTA and reimbursement listing continue in parallel, and reimbursement may be determined earlier than under the previous system

Strategic Implications

For manufacturers, this pathway:

• Reduces time to revenue — Devices can be used (and sold) in clinical practice within months rather than over a year
• Requires stronger clinical data — The trade-off is more rigorous clinical evaluation during the MFDS approval phase
• Does not guarantee reimbursement — The device enters clinical use, but reimbursement pricing is determined separately and may follow later
• Favors innovative technologies — The pathway is specifically designed for devices meeting innovation criteria, not incremental improvements

Pricing and Payment Systems

For Reimbursed Medical Devices

Aspect	Details
Price determination	HIRA determines eligibility; NHIS negotiates MRP
Reference pricing	A8 country prices + other OECD references
Co-payment	Patient pays 20–60% depending on category
Fee-for-service	93% of NHI payments are fee-for-service
Price revision	Existing product prices are periodically reviewed and adjusted downward

For Non-Reimbursed Medical Devices

For devices not covered by NHI, the final seller (typically the hospital or clinic) independently sets the price based on market dynamics. Patients pay the full cost out-of-pocket. This creates a two-tier market:

• Reimbursed devices — Lower unit prices but higher volume; subject to HTA and price controls
• Non-reimbursed devices — Higher prices but limited to patients willing/able to pay; no price controls

Digital Therapeutics (DTx) Reimbursement

South Korea has been a pioneer in DTx reimbursement. Since 2023, DTx products receive 3-year temporary registration for national reimbursement, restricted to prescribed patients within NECA-designated research or clinical trial institutions. After 3 years of evidence generation, a final decision on permanent reimbursement is made.

Market Access for Foreign Suppliers

Entry Requirements

Requirement	Details
KLH appointment	Mandatory for all foreign manufacturers
MFDS approval	Required for Class II–IV devices
ISO 13485 certification	Expected as part of technical documentation
Clinical data	Required for Class III/IV; may require Korean clinical trials
Korean-language labeling	Required for all products sold in Korea
KGMP compliance	Korean Good Manufacturing Practice (may leverage MDSAP)

Distribution Structure

Foreign medical devices typically enter Korea through:

1. Direct subsidiary — Establish a local office; highest control and investment
2. Exclusive distributor — Partner with a Korean distributor; most common approach
3. KLH + separate distributor — KLH handles regulatory; separate distributor handles commercial sales

Market Opportunities by Segment

Segment	Opportunity Level	Notes
Digital health / AI / SaMD	Very High	Government actively promoting; 113 categories eligible for immediate entry
IVD reagents	High	83 categories eligible for immediate entry; strong domestic demand
Robotic surgery	High	Eligible for immediate entry pathway; growing adoption
Advanced imaging	Moderate	Replacement demand post-doctors' strike
Consumables	Moderate–High	Large volume but price-competitive; dominated by domestic manufacturers
Rehabilitation devices	Growing	Aging population driving demand

Post-Doctor Strike Recovery (2026)

The 2024–2025 junior doctors' strike significantly disrupted the Korean healthcare market. Hospitals postponed equipment purchases and infrastructure upgrades. As of early 2026:

• Hospitals are resuming deferred equipment replacement
• Procurement departments are requesting extended payment terms
• Market recovery is expected to be gradual through 2026
• Growth will be driven by replacement demand and government digital health initiatives

Practical Checklist for Market Entry

Regulatory Pathway

• Appoint a qualified Korea License Holder (KLH)
• Classify your device under the Korean system (Class I–IV)
• Prepare technical documentation in Korean
• Submit MFDS/NIDS application
• Complete any required clinical evaluation

Reimbursement Pathway

• Determine whether your device requires HTA (new medical procedure?)
• If eligible for Immediate Market Entry pathway, coordinate with KLH on strengthened clinical data
• Apply for HIRA coverage determination within 30 days of MFDS approval
• Prepare cost-effectiveness and pricing evidence (A8 country reference pricing)
• Submit reimbursement listing application with proposed price justification
• Engage with NHIS on MRP negotiation

Commercial Strategy

• Evaluate KLH vs. separate distributor for commercial sales
• Consider dual strategy: non-reimbursed launch while pursuing reimbursement
• Budget for extended timeline (12–18 months for reimbursement listing under standard pathway)
• Build relationships with Key Opinion Leaders at major Korean hospitals
• Prepare Korean-language clinical and promotional materials

Key Takeaways

1. MFDS approval is necessary but not sufficient — Korea's HTA system means that regulatory clearance alone does not guarantee clinical adoption or reimbursement. Plan for both regulatory and reimbursement timelines.

2. The Immediate Market Entry pathway is a game-changer for innovative devices — Launched January 2026, it reduces time to clinical use from up to 490 days to 80–140 days for 199 designated device categories, primarily AI, digital health, and robotic devices.

3. HTA is the real gatekeeper — Korea's HTA is more stringent than in most comparable markets. Failure to demonstrate clinical validity blocks both reimbursement and clinical adoption. Invest in clinical evidence generation early.

4. Pricing references A8 countries — Korea uses External Reference Pricing against the US, Japan, UK, France, Germany, Italy, Switzerland, and Canada (added January 2023). Your Korean pricing strategy must be considered in the context of your global pricing architecture.

5. A Korea License Holder is mandatory — Foreign manufacturers cannot directly hold marketing authorization. Choose your KLH carefully, as this entity controls your regulatory footprint in Korea.